Paris Course On Revascularization In Brief
This article was originally published in The Gray Sheet
Executive Summary
Enter CoStar: Cobalt-chromium paclitaxel-eluting stent is associated with 2.9% target lesion revascularization (TLR) rate and 7.6% major adverse event rate in 12-month follow-up results of 145-patient EuroSTAR trial, presented by Keith Dawkins, MD, Southampton University Hospital, England. The firm recently launched the 1,700-patient, 90-site COSTAR-II pivotal study. The non-inferiority trial compares CoStar with Boston Scientific's Taxus (1"The Gray Sheet" May 16, 2005, p. 17)...
You may also be interested in...
Conor Set To Enroll Pivotal U.S. Study For CoStar, Talks Up DES Pipeline
Conor Medsystems expects to begin enrolling a 1,700-patient, U.S. pivotal trial for itsCoStar paclitaxel-eluting, cobalt-chromium coronary stent in the next few weeks
J&J Longs For Cypher Longevity, May Enjoy 15-Month Monopoly In Japan
Cordis aims to expand the U.S. shelf life of its Cypher sirolimus-eluting stent after resolving manufacturing issues cited by FDA in an April 2004 warning letter
J&J Reveling In RAVEL Drug-Coated Stent Data: No Restenosis At Six Months
Johnson and Johnson/Cordis' European RAVEL study data sets a high standard for other drug-coated stent developers, including no restenosis at six-month follow-up.